Teva Settles Cephalon Generics Case With F.T.C. for $1.2 Billion - The New York Times
Teva abused patent system and spread misinformation about a Copaxone rival, European officials say
Teva Under Suspicion On Practices To Stave Off Copaxone Competition
Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions
Case studies in Strategy: Teva
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK | Reuters
Teva's Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing | Ctech
Brussels' Teva probe reveals dark side of patent protections | Financial Times
Teva Q1 2023 Earnings: A Mix Of Challenges And Opportunities | Seeking Alpha
Teva slide could draw vultures but it won't be easy prey | The Times of Israel
Gilead And Teva's HIV Antitrust Trial Begins
Teva: Pricing In A Worst-Case Copaxone Scenario (NYSE:TEVA) | Seeking Alpha
Antitrust: Commission fines Teva and Cephalon €60.5 million
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
Judge Narrows Antitrust Case Against Teva Over Gilead HIV Drugs -
Teva Pharm expects U.S. opioid case settlements to cost $2.6 bln | Reuters
Men's Hurricane XLT2 – Sports Basement
Case studies in Strategy: Teva
Update On The Teva Copaxone EU Case. The EU Commission Issues A Statement Of Objections Against Teva Over Alleged Anti-Competitive Conduct Consisting Of Misuse Of Divisional Patents And A Disparagement Campaign Against
Antitrust: Commission sends Statement of Objections to Teva on 'pay for delay' pharma agreement
Teva asks high court to overturn recent GSK skinny label loss
Teva stocks fall after company said named in US price-fixing drug 'cartel' probe | The Times of Israel
Teva Is Easy Pill to Swallow - WSJ
Teva Hit With New Lawsuit Over Proposed Korlym Drug Copy
Synthon succeeds with Brinkhof and BarentsKrans in jurisidiction claim against Teva - JUVE Patent
Ranbaxy, Teva settle US anti-competition case | Mint
Teva neck-deep in legal trouble with no end in sight | Ctech
